Research Paper Volume 13, Issue 18 pp 22528—22543

Inhibition of FSTL3 abates the proliferation and metastasis of renal cell carcinoma via the GSK-3β/β-catenin signaling pathway

FSTL3 modulated GSK-3β/β-catenin pathway activation. (A, B) The A498 and ACHN cells were transiently transfected along with the overexpression plasmids of FSTL3. Western Blot experiment was done to verify the protein expressions of GSK-3β/β-catenin, and BMP1, SMAD1, SMAD2, and SMAD3 in RCC cells. (C, D) The A498 and ACHN cells were transiently transfected along with si-FSTL3. Western Blot was implemented to check the protein profiles of GSK-3β/β-catenin, and BMP1, SMAD1, SMAD2, and SMAD3 in RCC cells. (E, F) Western blot examined GSK-3β, β-catenin, BMP1, SMAD1, SMAD2, and SMAD3 in the formed tumor tissues. **PP

Figure 6. FSTL3 modulated GSK-3β/β-catenin pathway activation. (A, B) The A498 and ACHN cells were transiently transfected along with the overexpression plasmids of FSTL3. Western Blot experiment was done to verify the protein expressions of GSK-3β/β-catenin, and BMP1, SMAD1, SMAD2, and SMAD3 in RCC cells. (C, D) The A498 and ACHN cells were transiently transfected along with si-FSTL3. Western Blot was implemented to check the protein profiles of GSK-3β/β-catenin, and BMP1, SMAD1, SMAD2, and SMAD3 in RCC cells. (E, F) Western blot examined GSK-3β, β-catenin, BMP1, SMAD1, SMAD2, and SMAD3 in the formed tumor tissues. **P<0.01, ***P<0.001 (vs. NC or si-NC group). N=5.